Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 314
Filtrar
2.
Mycoses ; 67(1): e13690, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-38214347

RESUMEN

BACKGROUND: Treatment of onychomycosis is still challenging and warrants the development of new treatment strategies. Different trials were conducted to increase the penetration and efficacy of topical antifungals aiming at finding an alternative treatment especially when systemic antifungals are contraindicated. OBJECTIVES: To evaluate the efficacy of trichloroacetic acid (TCA) 100% either alone or combined with topical tioconazole 28% versus itraconazole pulse therapy in the treatment of onychomycosis. PATIENTS/METHODS: Forty-five patients with onychomycosis were divided into three groups: group (A) treated by topical TCA 100% for 12 sessions, group (B) treated by TCA 100% for 12 sessions combined with topical tioconazole 28% for 18 weeks and group (C) treated by itraconazole (400 mg/day for 1 week/month for 4 months). RESULTS: TCA 100% combined with topical tioconazole 28% showed the highest therapeutic response; however, the difference between the groups was statistically insignificant. Mycological cure (negative culture) was reported in 66.7% of group B versus 60% of group A and 40% of group C at the 20 week. CONCLUSIONS: TCA 100% is an effective and safe treatment option for onychomycosis especially when combined with antifungals. This modality is promising in the treatment of onychomycosis especially with the increased resistance to different antifungals.


Asunto(s)
Dermatosis del Pie , Imidazoles , Onicomicosis , Humanos , Itraconazol/uso terapéutico , Onicomicosis/tratamiento farmacológico , Antifúngicos/uso terapéutico , Ácido Tricloroacético/uso terapéutico , Resultado del Tratamiento , Dermatosis del Pie/tratamiento farmacológico
3.
Infect Dis (Lond) ; 56(4): 299-307, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38217494

RESUMEN

PURPOSE: This study aimed to compare trichloroacetic acid (TCA) versus electrocautery (ECA) for the treatment of anal high-grade squamous intraepithelial lesions (HSIL). METHODS: This is an observational, single-center study. All subjects with HIV who had anal HSIL treated with TCA or ECA from 2010 to 2022 were included. Effectiveness was evaluated by on-treatment analysis, defining response as the resolution of HSIL and recurrence as a new diagnosis of HSILs during follow-up. A propensity score analysis was used to adjust for confounding factors. RESULTS: In total, 227 and 260 HSIL episodes were treated with ECA and TCA, respectively. Response was observed in 61.7% (95% CI: 55.3-68) of cases treated with ECA and in 73.1% (95% CI: 67.8-78.5) with TCA (p = .004). The effectiveness of TCA was higher in large and multifocal HSILs. Side effects were common with both treatments, but no serious events were described. Tolerability was good in 77.1% and 80.7% of patients treated with ECA and TCA, respectively. At 24 months, recurrent HSIL were observed in 36.3% (95% CI: 27.3-45) and 28% (95% CI: 20.2-35.8) in the ECA and TCA groups (p = .049). A nadir CD4 cell count ≤200 cells/µl was found to be a risk factor for recurrence (OR: 1.77; 95% CI: 1.12-2.78). CONCLUSIONS: In this study, treatment with TCA showed high effectiveness, low recurrence and good tolerability. Considering the benefits of TCA, it could be considered one of the first-line treatments for anal HSIL.


Asunto(s)
Neoplasias del Ano , Infecciones por VIH , Infecciones por Papillomavirus , Lesiones Intraepiteliales Escamosas , Humanos , Masculino , Ácido Tricloroacético/uso terapéutico , Infecciones por VIH/complicaciones , Infecciones por VIH/tratamiento farmacológico , Resultado del Tratamiento , Neoplasias del Ano/tratamiento farmacológico , Neoplasias del Ano/patología , Electrocoagulación , Homosexualidad Masculina
4.
J Pediatr Surg ; 59(4): 678-683, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-37978000

RESUMEN

BACKGROUND: Recurrent tracheoesophageal fistula (rTEF) is a well-known complication after surgery of EA, occurring in roughly 3-10% of the patients. Recent studies have highlighted safety and efficacy of endoscopic management of recurrent TEF. The aim of this study was to evaluate the efficacy of chemocauterization with trichloroacetic acid (TCA) in rTEF and congenital tracheoesophageal fistula (cTEF). METHODS: Retrospective chart review of consecutive patients with recurrent or congenital TEF who underwent endoscopic chemo-cauterization between 2018 and 2022 at a tertiary center. Children diagnosed with TEF who underwent primary or secondary endoscopic treatment were included. Median follow up time was 19 months for rTEF and 33 months for cTEF. RESULTS: During the study period, 18 patients were treated endoscopically by chemocatuerization with TCA at our institution. Treatment of recurrent TEF was successful in 13 of 14 patients (93%) Treatment of congenital TEF was successful in 2 of 4 patients (50%). In 14 patients, closure was seen after 1-2 treatments. There were no serious adverse reactions or complications to the endoscopic treatment of TEF. CONCLUSION: Endoscopic chemocauterization is a minimal invasive technique with low morbidity and high success rate and may be considered as primary treatment for recurrent TEF. LEVEL OF EVIDENCE: III.


Asunto(s)
Atresia Esofágica , Fístula Traqueoesofágica , Niño , Humanos , Lactante , Fístula Traqueoesofágica/cirugía , Fístula Traqueoesofágica/complicaciones , Atresia Esofágica/cirugía , Atresia Esofágica/complicaciones , Ácido Tricloroacético/uso terapéutico , Estudios Retrospectivos , Recurrencia Local de Neoplasia/cirugía , Cauterización/métodos , Resultado del Tratamiento
7.
Skinmed ; 21(5): 330-335, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37945358

RESUMEN

Xeroderma pigmentosum (XP) is a rare autosomal recessive disease; relatively mild XP patients are sometimes designated as having pigmented xerodermoid or xerodermoid pigmentosum (XP-V), a variant of XP. It is commonly associated with many long-standing skin conditions and tumors, including malignancies, management of which is necessary to prevent the progress of the disease. The objective of the study was to report the use of a number of innovative therapeutic and prophylactic treatments, beyond surgery, such as topical 5-fluorouracil, topical imiquimod, other topical immunomodulators, or photodynamic therapy, in treating skin eruptions and their complications in XP patients. This was a prospective therapeutic interventional study in which 50 patients with XP-V were evaluated. Age of subjects ranged from 2 to 50 years with a mean age of 18 years. This study was divided into two parts. In part one, patients were treated by applying topical zinc sulfate 25% twice daily on entire face for 2 months, then once daily for several months or years. In another instance, two women were treated with heat dermabrasion with needle diathermy on the entire face under local anesthesia, followed by application of trichloroacetic acid 35% peeling in a single session. In part two, topical podophyllin 25% was used as therapy for 18 patients, all of whom had XP complications, such as keratoacanthoma, basal cell carcinomas and squamous cell cancers.1 Podophyllin was applied to the lesions until complete resolution was documented. All patients treated with topical zinc sulfate 25% responded well as determined by clearance of actinic keratoses (ActK) and small malignant lesions, minimization of pigmented freckles, prevention of new lesions, and ceased progress of eruptions. Heat dermabrasion administered in a single session resulted in the clearance of pigmented freckles, ActK, and small tumors, and cessation of new eruptions during follow-up that continued for up to 6 years.


Asunto(s)
Queratosis Actínica , Melanosis , Neoplasias Cutáneas , Xerodermia Pigmentosa , Humanos , Femenino , Adolescente , Preescolar , Niño , Adulto Joven , Adulto , Persona de Mediana Edad , Xerodermia Pigmentosa/complicaciones , Xerodermia Pigmentosa/tratamiento farmacológico , Xerodermia Pigmentosa/patología , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/prevención & control , Ácido Tricloroacético/uso terapéutico , Sulfato de Zinc/uso terapéutico , Dermabrasión , Calor , Podofilino/uso terapéutico
9.
Clin Otolaryngol ; 48(3): 451-456, 2023 05.
Artículo en Inglés | MEDLINE | ID: mdl-36645130

RESUMEN

OBJECTIVES: Granular myringitis (GM) is a troublesome disease with a high incidence of recurrence and relapse. CO2 laser vaporisation and trichloroacetic acid (TAA) have been applied in treating several otological diseases, both with favourable therapeutic efficacy. However, long-term therapeutic efficacy of both CO2 laser vaporisation and TAA cauterisation against GM has not yet been evaluated. We aimed to investigate the therapeutic potential of CO2 laser vaporisation and TAA cauterisation in GM management. STUDY DESIGN: Prospective and randomised study. PARTICIPANTS: A total of 88 GM patients who failed therapy with boric acid, alcohol and glycerin ear drop otic solution between July 2009 and January 2018 were included. Participants were randomly assigned to receive CO2 laser vaporisation (n = 39) or TAA cauterisation (n = 49). MAIN OUTCOME MEASURES: Main outcomes were treatment success, complications after 4 months of treatment, and recurrence within 4-12 months after treatment. RESULTS: The success rate was significantly higher in the CO2 group than in the TAA group (94.9% vs. 77.6%, p = .023). After 4 months of treatment, the GM recurrence rate was comparable between the two groups (13.5% vs. 18.4%, p = .562). The CO2 laser group had one case of perforation and one case of severe vertigo, whereas one participant in the TAA cauterisation group experienced hearing loss. CONCLUSION: Both TAA cauterisation and CO2 laser vaporisation are safe and effective treatments for GM. The success rate of CO2 laser vaporisation for treating GM is higher than that of TAA cauterisation. Recurrence rates are comparable within 1 year.


Asunto(s)
Cáusticos , Terapia por Láser , Láseres de Gas , Otitis Media , Humanos , Estudios Prospectivos , Dióxido de Carbono , Láseres de Gas/uso terapéutico , Membrana Timpánica , Resultado del Tratamiento , Ácido Tricloroacético/uso terapéutico , Cauterización
10.
Food Funct ; 13(19): 10134-10146, 2022 Oct 03.
Artículo en Inglés | MEDLINE | ID: mdl-36106708

RESUMEN

Emerging evidence suggests that sea cucumber ether phospholipids (ether-PLs) can modulate high-fat diet (HFD)-induced metabolic disorders. However, whether this modulation is associated with metabolic pathways related to oxidative stress and inflammation remains unclear. This study aimed to investigate the antioxidative and anti-inflammatory effects on HFD-fed mice and the associated metabolism pathways in response to administration with sea cucumber ether-PLs using integrated biochemistry and a metabolomics approach. Biochemistry analysis and histological examinations showed that sea cucumber ether-PLs significantly decreased body weight gain and fat deposition in tissues. PE-P was superior to PC-O in alleviating reactive oxygen species (ROS), malondialdehyde (MDA) and inflammatory responses (IL-6, TNF-α and MCP-1) in the HFD-induced mouse model. Serum metabolomics analysis revealed that it upregulated four metabolites and downregulated twenty-four metabolites compared to those in HFD mice after ether-PL administration. Pathway analysis indicated that sea cucumber ether-PLs alleviate the HFD-induced inflammation and oxidative stress by three main metabolic pathways, namely fatty acid metabolism, branched-chain amino acid (BCAA) metabolism, and trichloroacetic acid (TCA) metabolism. Taken together, sea cucumber ether-PLs showed great potential to become a natural functional food against oxidative stress and inflammation caused by HFD.


Asunto(s)
Dieta Alta en Grasa , Pepinos de Mar , Aminoácidos de Cadena Ramificada/metabolismo , Animales , Antiinflamatorios/farmacología , Dieta Alta en Grasa/efectos adversos , Ácidos Grasos/farmacología , Inflamación/tratamiento farmacológico , Inflamación/metabolismo , Interleucina-6/metabolismo , Malondialdehído , Ratones , Ratones Endogámicos C57BL , Estrés Oxidativo , Éteres Fosfolípidos/farmacología , Éteres Fosfolípidos/uso terapéutico , Especies Reactivas de Oxígeno , Pepinos de Mar/metabolismo , Ácido Tricloroacético/farmacología , Ácido Tricloroacético/uso terapéutico , Factor de Necrosis Tumoral alfa/metabolismo
11.
Dermatol Surg ; 48(8): 838-842, 2022 08 01.
Artículo en Inglés | MEDLINE | ID: mdl-35917264

RESUMEN

BACKGROUND: Keratosis pilaris (KP) is a common disorder of keratinization with different therapeutic modalities; however, none of them is completely satisfactory. OBJECTIVE: Assess and compare the efficacy of trichloroacetic acid (TCA) 20% and long-pulsed 1,064-nm Nd:YAG laser in the treatment of KP. MATERIALS AND METHODS: Twenty patients with symmetrically distributed areas of KP were enrolled in this study. In each patient, 2 symmetrical KP areas were randomly assigned to receive 4 sessions of either long-pulsed Nd:YAG laser or TCA 20%. Clinical evaluation by Investigator Global Assessment (IGA) was done by 2 blinded physicians after treatment. Dermoscopic assessment was done at baseline and at the end point of the study. RESULTS: Investigator Global Assessment of laser-treated area showed that 2 patients (10%) had moderate improvement, 10 patients (50%) had marked improvement, and 8 patients (40%) had excellent improvement. Investigator Global Assessment of TCA-treated area showed that 9 patients (45%) had marked improvement and 11 patients (55%) had excellent improvement. Dermoscopic score of KP showed a significant reduction with both modalities. The IGA and reduction in dermoscopic scores were comparable between the 2 modalities. CONCLUSION: Both long-pulsed 1,064-nm Nd:YAG laser and 20% TCA are effective in the treatment of KP. CLINICAL TRIAL REGISTRATION: Name of the trial register: clinicaltrial.gov . Registration number: NCT04797663.


Asunto(s)
Láseres de Estado Sólido , Anomalías Múltiples , Enfermedad de Darier , Cejas/anomalías , Humanos , Inmunoglobulina A , Láseres de Estado Sólido/uso terapéutico , Resultado del Tratamiento , Ácido Tricloroacético/uso terapéutico
13.
Asian Pac J Cancer Prev ; 23(3): 947-952, 2022 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-35345367

RESUMEN

PURPOSE: To compare the efficacy and safety of up to two-time administration of 85% TCA, as a promising alternative therapy to conservative and surgical management of grade one to three CINs. METHODS: In this two-armed randomized clinical trial, a total of 53 patients with biopsy-proven CIN lesions were allocated to two groups of TCA treatment. The first group (n=26) received a single dose of local therapy with 85% TCA while the second group (n=27) was treated on two separate occasions with a two-week interval. Two participants (one in each group) were lost to follow-up. At the two-month follow-up after TCA application, a colposcopy-guided biopsy was performed for all patients and the pathological specimens were studied by a single experienced pathologist to determine the post-intervention grading of CIN. RESULTS: Two groups were comparable in terms of age and base-line lesion grading, as CIN 1 lesions comprised the majority of cases (54%), followed by CIN 2(37%). While our sample was a poor representative of CIN3 lesions (7%), no significant difference was noticed between the single and twice TCA treated groups with a response rate of 52% and 54% respectively (either complete remission to normal histology or regression to any low-grade lesion). Either separate analysis (with respect to the base-line grading within each treatment group) or combined analysis (regardless of CIN sub-group) could not generate any statistical significance. The second dose of TCA did not increase the frequency of reported adverse events. CONCLUSION: The second dose of topical 85% TCA does not seem to increase the CIN response rate more so than its single dose. However, further controlled clinical trials with larger samples are warranted to verify current findings. The use of TCA was not limited by any major side effect, therefore, the potential to achieve an increased efficacy with more frequent TCA applications is appealing.


Asunto(s)
Displasia del Cuello del Útero , Neoplasias del Cuello Uterino , Colposcopía , Femenino , Humanos , Embarazo , Inducción de Remisión , Ácido Tricloroacético/uso terapéutico , Neoplasias del Cuello Uterino/tratamiento farmacológico , Neoplasias del Cuello Uterino/patología , Displasia del Cuello del Útero/tratamiento farmacológico , Displasia del Cuello del Útero/patología
15.
J Dermatolog Treat ; 33(2): 959-964, 2022 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-32649234

RESUMEN

Melasma is common skin condition presenting with hyperpigmentation. To evaluate the efficacy, tolerance, and complications of one session of combined chemical peels compared to traditional serial sessions of trichloroacetic acid (TCA) peeling in treating melasma. One session of combined chemical peels was carried out at the left side of the face, while six sessions of TCA 15% peel were carried out at the right side of the face every 10 days. The Modified Melasma Area and Severity Index (MASI) score was calculated at baseline (before starting peeling sessions), after one month (at the fourth TCA peeling session), and after three months (one month after the last TCA peeling session). Both sides of the face showed gradual reduction in modified MASI score throughout sessions. By the end of the study, the TCA-treated side showed slightly lower mean modified MASI score than the combined chemical peels-treated side of the face; however this difference was not statistically significant, (p = .405). A single session of combined chemical peels is as effective as six sessions of TCA peel in treatment of melasma. Combined chemical peels can be used as a convenient, tolerable and time saving safe procedure for treating melasma.


Asunto(s)
Quimioexfoliación , Hiperpigmentación , Melanosis , Quimioexfoliación/métodos , Humanos , Melanosis/tratamiento farmacológico , Resultado del Tratamiento , Ácido Tricloroacético/uso terapéutico
17.
J Cosmet Dermatol ; 21(1): 247-253, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-33749961

RESUMEN

BACKGROUND: Treatment of acanthosis nigricans (AN) is challenging, and new modalities are being explored continuously to increase the therapeutic efficacy. AIM: To evaluate the efficacy and safety of fractional CO2 laser compared to trichloroacetic acid (TCA) peel in the treatment of pseudo-acanthosis nigricans (pseudo-AN). METHODS: The study included 40 patients with pseudo-AN on the neck and axilla allocated into two groups each containing 20 patients. Group (A) was treated with TCA 20% peel applied on the pigmented area while group (B) received fractional CO2 laser. Both treatments were performed till complete clearance or for a maximum of four treatment sessions. Patients with excellent response were further followed up for 6 months after the end of treatment. RESULTS: Both modalities were effective in the treatment of pseudo-AN; however, the therapeutic response was significantly higher in the fractional CO2 laser group compared to the TCA peel group (p < 0.01). Marked to excellent response (51%-100% clearance of AN lesions) was achieved in 85% of the patients in the fractional laser group versus 10% of the patients in the TCA group. Adverse effects, for example, persistent erythema, post-inflammatory hyperpigmentation, and burning sensation, were also statistically higher in the TCA group compared to the laser group (p = 0.04). CONCLUSION: Fractional CO2 laser is a promising effective and well-tolerated treatment modality for pseudo-acanthosis nigricans.


Asunto(s)
Acantosis Nigricans , Quimioexfoliación , Láseres de Gas/uso terapéutico , Ácido Tricloroacético/uso terapéutico , Acantosis Nigricans/terapia , Dióxido de Carbono , Eritema/etiología , Humanos , Láseres de Gas/efectos adversos , Resultado del Tratamiento , Ácido Tricloroacético/efectos adversos
18.
Top Companion Anim Med ; 46: 100594, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-34715377

RESUMEN

Apocrine hidrocystoma (AH) is a benign cystic lesion infrequently reported in the eyelids of cats. There are several reports of application of trichloroacetic acid (TCA) for treatment of eyelid apocrine hidrocystomas with high success rates in humans. This is the first report of intralesional injection of TCA for the treatment of eyelid AH in a feline. A 12-year-old Persian female spayed cat has been presented for evaluation of cystic masses on the eyelids. The cat had signs of ocular discomfort and two large cysts on the lower eyelid of the right eye. Ophthalmic examination was suggestive of eyelid AH. The cat underwent general anesthesia, and TCA 20 % was injected intracystically. The diagnosis of AH was confirmed by cytology. Two years later, there was no recurrence of the cyst. This case highlights the successful treatment of a large AH in the eyelids of a cat with TCA. Findings suggest that chemical ablation with TCA may be a useful treatment for AH in cats.


Asunto(s)
Enfermedades de los Gatos , Hidrocistoma , Neoplasias de las Glándulas Sudoríparas , Animales , Enfermedades de los Gatos/tratamiento farmacológico , Gatos , Párpados , Femenino , Hidrocistoma/tratamiento farmacológico , Hidrocistoma/veterinaria , Inyecciones/veterinaria , Neoplasias de las Glándulas Sudoríparas/tratamiento farmacológico , Neoplasias de las Glándulas Sudoríparas/veterinaria , Ácido Tricloroacético/uso terapéutico
19.
J Cosmet Dermatol ; 21(1): 327-330, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-34773721

RESUMEN

BACKGROUND: The Chemical Reconstruction of Skin Scars (CROSS) technique was first described in 2002 and has since demonstrated safety and efficacy in multiple studies. We describe the treatment of six patients with a modified version of the CROSS method-the Painting CROSS trichloroacetic acid (TCA) technique. This technique has the advantage of offering even higher tissue selectivity and better control of the scar edges, enhancing both safety and efficacy. METHODS: We retrospectively evaluated 31 scars of six patients who underwent a single treatment by the Painting CROSS TCA method. A 0.3 ml insulin syringe with a 30-gauge needle was filled with 0.05 ml of 85% TCA solution and then applied to the scar base with slight pressure until frosting was achieved. Patients were evaluated before and 3 months after treatment for scar volume deficit by a high-resolution three-dimensional imaging system. RESULTS: The average volume of the 31 scars assessed in our study was 2.71 mm3 before treatment and 1.96 mm3 after treatment. There was a 26.3% average decrease in the volume of the scars after one treatment. Transient mild hyperpigmentation was noted in two patients after the treatment. CONCLUSION: Painting CROSS TCA technique has demonstrated efficacy in the treatment of acne scars after a single treatment.


Asunto(s)
Acné Vulgar , Ácido Tricloroacético , Acné Vulgar/complicaciones , Cicatriz/etiología , Cicatriz/patología , Humanos , Estudios Retrospectivos , Resultado del Tratamiento , Ácido Tricloroacético/uso terapéutico
20.
Photodiagnosis Photodyn Ther ; 35: 102465, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34333146

RESUMEN

OBJECTIVES: This is a randomized controlled clinical trial comparing Photodynamic Therapy (PDT) and the application of trichloracetic acid (TAA) in the treatment of HPV condyloma in the perianal and vulva regions. Design, Randomised controlled, open label, trial. They were allocated to each treatment following randomization by a computer program. SETTING: Women Health Ambulatory in São Carlos city, São Paulo State in the Brazil. PARTICIPANTS: 36 patients evaluated. 31 patients fulfilled the study requirements. INTERVENTION: Photodynamic Therapy (PDT) versus trichloracetic acid (TAA). The PDT protocol used the prodrug methyl aminolevulinate incubated for 3 hours and irradiation at 630 nm (100 J/cm²). In the treatment using TAA, warts received a small amount of acid using a cotton swab. Both treatments were repeated weekly until the lesions disappeared completely or until 10 sessions were completed. MAIN OUTCOME MEASURE: Clinical analysis. Follow-up between 12 and 30 months after the complete treatment. RESULTS: A total of 16 patients were treated with PDT and 15 patients with TAA. A complete response rate of 60% for TAA and 63% for PDT, with a recurrence rate of 33% for TAA and 0% for PDT. CONCLUSION: PDT appears not only to treat lesions due to physical destruction of condyloma and subclinical lesions, but also to modulate the immune system and/or also to decrease the local viral load, suggesting a lower recurrence compared to the TAA group.


Asunto(s)
Condiloma Acuminado , Infecciones por Papillomavirus , Fotoquimioterapia , Ácido Aminolevulínico/uso terapéutico , Brasil , Condiloma Acuminado/tratamiento farmacológico , Femenino , Humanos , Infecciones por Papillomavirus/tratamiento farmacológico , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/uso terapéutico , Ácido Tricloroacético/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA